Publicaciones de Jorge Federico Elgart

2019

  • Economic Benefit of Sponsored Controlled Clinical Trials: The Avoidable Cost in Drugs for the Treatment of Rheumatoid Arthritis. Liberman, F., Elgart, J., Strusberg, I.(2019) Value in Health Regional Issues, 20, pp. 7-11.DOI: 10.1016/j.vhri.2018.10.007
  • Clinical and Economic Value of p16INK4a for the Differential Diagnosis of Morphologic Cervical Intraepithelial Neoplasia 2. Fishkel, V.S., Monge, F.C., Von Petery, F.M., Tapper, K.E., Peña, T.M., Torres, F., Poletta, F.A., Elgart, J.F., Avagnina, A., Denninghoff, V. (2019) Applied Immunohistochemistry and Molecular Morphology, 27 (9), pp. 672-677. DOI: 10.1097/PAI.0000000000000674
  • Treat-to-target HbA1c and lipid profile to prolong beta-cell mass/function and optimize treatment goal attainment. Gagliardino, J.J., Elgart, J., Forti, L., Guaita, M.S., Chantelot, J.M.(2019) Diabetes/Metabolism Research and Reviews, 35 (6), art. no. e3166,DOI: 10.1002/dmrr.3166
  • Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015. Tabesh, M., Magliano, D.J., Tanamas, S.K., Surmont, F., Bahendeka, S., Chiang, C.-E., Elgart, J.F., Gagliardino, J.J., Kalra, S., Krishnamoorthy, S., Luk, A., Maegawa, H., Motala, A.A., Pirie, F., Ramachandran, A., Tayeb, K., Vikulova, O., Wong, J., Shaw, J.E. (2019) Acta Diabetologica, 56 (8), pp. 889-897. DOI: 10.1007/s00592-018-01284-4
  • Type 2 diabetes: Prescription patterns and treatment outcomes of IDMPS survey in Argentina. Gagliardino, J.J., Elgart, J., Forti, L., Ivanna, Q., Chantelot, J.M.(2019) Diabetes Research and Clinical Practice, 153, pp. 86-92. DOI: 10.1016/j.diabres.2019.05.008
  • Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015. Tabesh, M., Magliano, D.J., Tanamas, S.K., Surmont, F., Bahendeka, S., Chiang, C.-E., Elgart, J.F., Gagliardino, J.J., Kalra, S., Krishnamoorthy, S., Luk, A., Maegawa, H., Motala, A.A., Pirie, F., Ramachandran, A., Tayeb, K., Vikulova, O., Wong, J., Shaw, J.E. (2019) Diabetic Medicine, 36 (7), pp. 878-887. DOI: 10.1111/dme.13858
  • Drug treatment of type 2 diabetes: Its cost is significantly associated with HbA1c levels. Elgart, J.F., Silvestrini, C., Prestes, M., Gonzalez, L., Rucci, E., Gagliardino, J.J. (2019) International Journal of Clinical Practice, 73 (4), art. no. e13336. DOI: 10.1111/ijcp.13336

2018

  • Diabetes primary prevention program: New insights from data analysis of recruitment period. Gagliardino JJ, Elgart JF, Bourgeois M, Etchegoyen G, Fantuzzi G, Ré M, Ricart JP, García S, Giampieri C, González L, Suárez-Crivaro F, Kronsbein P, Angelini JM, Martínez C, Martínez J, Ricart A, Spinedi E. Diabetes Metab Res Rev. 2018 Jan;34. doi: 10.1002/dmrr.2943. Epub
  • Diabetes tipo 2: patrones prescriptivos y resultados del tratamiento en IDMPS (International diabetes management practices study) en Argentina. Gagliardino JJ, Elgart JF, Forti L, Querzoli I, De Luca J, Chatelau J. XXI Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Revista de la SAD. 2018; 52:81.
  • Tratamiento farmacológico de la diabetes tipo 2: su costo está significativamente asociado con los niveles de HbA1c. Elgart JF, Silvestrini C, Prestes M, Gonzalez L, Rucci E, Gagliardino JJ. XXI Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Revista de la SAD. 2018; 52:95-96.
  • Ingesta alimentaria en la población adulta de dos ciudades de la Provincia de Buenos Aires: su adecuación a las recomendaciones nutricionales. García S, Fantuzzi G, Angelini JM, Bourgeois M, Elgart JF, Etchegoyen G, Giampieri C, González L, Kronsbein P, Martínez C, Martínez J, Prestes M, Ré M, Ricart A, Ricart JP, Gagliardino JJ. Actualización en Nutrición. 2018 Jun; 19(2): 38-43. (ISSN 1667-8052).